• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

老年 2 型糖尿病患者的新型降糖治疗药物。

Newer Glucose-Lowering Therapies in Older Adults with Type 2 Diabetes.

机构信息

AdventHealth Translational Research Institute, 301 East Princeton Street, Orlando, FL 32804, USA.

AdventHealth Translational Research Institute, 301 East Princeton Street, Orlando, FL 32804, USA; AdventHealth Diabetes Institute, 2415 North Orange Avenue, Suite 501, Orlando, FL 32804, USA.

出版信息

Endocrinol Metab Clin North Am. 2023 Jun;52(2):355-375. doi: 10.1016/j.ecl.2022.10.010. Epub 2023 Feb 20.

DOI:10.1016/j.ecl.2022.10.010
PMID:36948784
Abstract

Diabetes is prevalent in older adults and older adults with diabetes are more likely to have multiple comorbidities. It is, therefore, important to personalize diabetes management in this group. Newer glucose-lowering drugs, including dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists can be safely used in older patients and are preferred choices in many cases due to their safety, efficacy, and low risk of hypoglycemia.

摘要

糖尿病在老年人中较为常见,且患有糖尿病的老年人更有可能同时患有多种合并症。因此,对这一群体进行个体化的糖尿病管理非常重要。新型的降血糖药物,包括二肽基肽酶-4 抑制剂、钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽-1 受体激动剂,可安全用于老年患者,并且由于其安全性、疗效和低血糖风险低,在许多情况下都是首选。

相似文献

1
Newer Glucose-Lowering Therapies in Older Adults with Type 2 Diabetes.老年 2 型糖尿病患者的新型降糖治疗药物。
Endocrinol Metab Clin North Am. 2023 Jun;52(2):355-375. doi: 10.1016/j.ecl.2022.10.010. Epub 2023 Feb 20.
2
Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.新型降糖药物与二甲双胍联合治疗 2 型糖尿病的心血管疗效的性别差异。
J Am Heart Assoc. 2020 Jan 7;9(1):e012940. doi: 10.1161/JAHA.119.012940. Epub 2020 Jan 4.
3
Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂、胰高血糖素样肽 1 激动剂和二肽基肽酶 4 抑制剂与 2 型糖尿病患者肾脏结局的关系:系统评价和网络荟萃分析。
PLoS One. 2022 Apr 14;17(4):e0267025. doi: 10.1371/journal.pone.0267025. eCollection 2022.
4
Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.新型降糖药物对 2 型糖尿病患者心力衰竭风险的比较:网络荟萃分析。
JACC Heart Fail. 2018 Oct;6(10):823-830. doi: 10.1016/j.jchf.2018.05.021. Epub 2018 Sep 5.
5
Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂、胰高血糖素样肽 1 受体激动剂和二肽基肽酶 4 抑制剂与 2 型糖尿病患者全因死亡率的关联:系统评价和荟萃分析。
JAMA. 2018 Apr 17;319(15):1580-1591. doi: 10.1001/jama.2018.3024.
6
Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.基于深度学习神经网络的机器学习对 2 型糖尿病使用钠-葡萄糖共转运蛋白 2 抑制剂、二肽基肽酶-4 抑制剂或胰高血糖素样肽-1 受体激动剂的心肌梗死的比例风险分析。
Curr Med Res Opin. 2020 Mar;36(3):403-409. doi: 10.1080/03007995.2019.1706043. Epub 2020 Jan 6.
7
Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.二甲双胍治疗的 2 型糖尿病中伴有中度心血管风险患者的附加治疗:一项全国性研究。
Cardiovasc Diabetol. 2020 Jul 6;19(1):107. doi: 10.1186/s12933-020-01078-5.
8
Comment on Kutz et al. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes Care 2023;46:2004-2014.对库茨等人的评论。2型糖尿病中根据虚弱程度比较钠-葡萄糖协同转运蛋白2抑制剂、胰高血糖素样肽-1受体激动剂和二肽基肽酶-4抑制剂的心血管有效性和安全性。《糖尿病护理》2023年;46:2004 - 2014。
Diabetes Care. 2024 Apr 1;47(4):e32-e33. doi: 10.2337/dc23-2420.
9
Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes.胰高血糖素样肽-1受体激动剂和钠-葡萄糖协同转运蛋白2抑制剂与2型糖尿病患者非酒精性脂肪性肝病风险
Diabetes Care. 2022 Apr 1;45(4):819-829. doi: 10.2337/dc21-1953.
10
Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients.新型抗糖尿病药物对斋月禁食糖尿病患者的有效性和安全性
J Diabetes Res. 2016;2016:6962574. doi: 10.1155/2016/6962574. Epub 2016 Aug 24.

引用本文的文献

1
PACAP and VIP Neuropeptides' and Receptors' Effects on Appetite, Satiety and Metabolism.垂体腺苷酸环化酶激活肽和血管活性肠肽神经肽及其受体对食欲、饱腹感和新陈代谢的影响。
Biology (Basel). 2023 Jul 17;12(7):1013. doi: 10.3390/biology12071013.